---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005084"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:25:56.141702+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences Q4 net loss $67M; ARC-7 domvanalimab combo doubles PFS to 12 months

## Summary
- Q4 2022 net loss $67M vs net income $280M in Q4 2021; full-year net loss $267M vs net income $53M.
- Revenue $34M in Q4 2022, down from $355M in Q4 2021; cash $1.1B, sufficient into 2026.
- ARC-7 interim data: domvanalimab+zimberelimab mPFS 12.0 months vs 5.4 months for zimberelimab alone.
- Four ongoing registrational Phase 3 studies for domvanalimab; updated ARC-7 data expected at ASCO June 2023.
- AB521 (HIF-2a inhibitor) Phase 1/1b enrolling 50mg cohort; initial data expected late 2023 or early 2024.

## SEC filing metadata
- accession: 0000950170-23-005084
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017023005084/0000950170-23-005084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017023005084/rcus-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005084
- JSON: https://secwatch.observer/filing/0000950170-23-005084.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005084.txt

## Key facts
- Earnings Releases
  Arcus Biosciences, Inc. reported financial results for the three months and full year ended December 31, 2022.
  - Period: the three months and full year ended December 31, 2022
  - Result: reported results
  source text: On February 28, 2023, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000095017023005084/0000950170-23-005084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.